PLUS THERAPEUTICS INC (PSTV) Fundamental Analysis & Valuation

NASDAQ:PSTV • US72941H5090

0.2947 USD
-0.01 (-4.22%)
At close: Mar 12, 2026
0.2615 USD
-0.03 (-11.27%)
Pre-Market: 3/13/2026, 8:01:20 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This PSTV fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

Overall PSTV gets a fundamental rating of 2 out of 10. We evaluated PSTV against 519 industry peers in the Biotechnology industry. PSTV scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. PSTV is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. PSTV Profitability Analysis

1.1 Basic Checks

  • PSTV had negative earnings in the past year.
  • In the past year PSTV has reported a negative cash flow from operations.
  • In the past 5 years PSTV always reported negative net income.
  • In the past 5 years PSTV always reported negative operating cash flow.
PSTV Yearly Net Income VS EBIT VS OCF VS FCFPSTV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

  • PSTV has a Return On Assets of -110.19%. This is in the lower half of the industry: PSTV underperforms 78.03% of its industry peers.
  • With a Return On Equity value of -407.06%, PSTV is not doing good in the industry: 74.57% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -110.19%
ROE -407.06%
ROIC N/A
ROA(3y)-132.52%
ROA(5y)-105.31%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PSTV Yearly ROA, ROE, ROICPSTV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for PSTV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PSTV Yearly Profit, Operating, Gross MarginsPSTV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. PSTV Health Analysis

2.1 Basic Checks

  • PSTV does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for PSTV has been increased compared to 1 year ago.
  • The number of shares outstanding for PSTV has been increased compared to 5 years ago.
  • PSTV has a worse debt/assets ratio than last year.
PSTV Yearly Shares OutstandingPSTV Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M
PSTV Yearly Total Debt VS Total AssetsPSTV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

  • Based on the Altman-Z score of -37.70, we must say that PSTV is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -37.70, PSTV is doing worse than 89.98% of the companies in the same industry.
  • There is no outstanding debt for PSTV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -37.7
ROIC/WACCN/A
WACC8.45%
PSTV Yearly LT Debt VS Equity VS FCFPSTV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M

2.3 Liquidity

  • A Current Ratio of 1.29 indicates that PSTV should not have too much problems paying its short term obligations.
  • With a Current ratio value of 1.29, PSTV is not doing good in the industry: 83.04% of the companies in the same industry are doing better.
  • PSTV has a Quick Ratio of 1.29. This is a normal value and indicates that PSTV is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.29, PSTV is doing worse than 82.47% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.29
Quick Ratio 1.29
PSTV Yearly Current Assets VS Current LiabilitesPSTV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. PSTV Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 32.54% over the past year.
  • PSTV shows a decrease in Revenue. In the last year, the revenue decreased by -8.16%.
  • PSTV shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -3.61% yearly.
EPS 1Y (TTM)32.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.19%
Revenue 1Y (TTM)-8.16%
Revenue growth 3YN/A
Revenue growth 5Y-3.61%
Sales Q2Q%-4.05%

3.2 Future

  • Based on estimates for the next years, PSTV will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.88% on average per year.
  • PSTV is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 89.59% yearly.
EPS Next Y88.56%
EPS Next 2Y38.61%
EPS Next 3Y25.07%
EPS Next 5Y15.88%
Revenue Next Year-1.68%
Revenue Next 2Y19.93%
Revenue Next 3Y62.94%
Revenue Next 5Y89.59%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
PSTV Yearly Revenue VS EstimatesPSTV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
PSTV Yearly EPS VS EstimatesPSTV Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -200K -400K -600K -800K -1M

More info and screens

Find the best growth stocksShow best growing peers

1

4. PSTV Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for PSTV. In the last year negative earnings were reported.
  • Also next year PSTV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PSTV Price Earnings VS Forward Price EarningsPSTV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PSTV Per share dataPSTV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

  • A more expensive valuation may be justified as PSTV's earnings are expected to grow with 25.07% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.61%
EPS Next 3Y25.07%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PSTV Dividend Analysis

5.1 Amount

  • No dividends for PSTV!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PSTV Fundamentals: All Metrics, Ratios and Statistics

PLUS THERAPEUTICS INC

NASDAQ:PSTV (3/12/2026, 8:05:57 PM)

Premarket: 0.2615 -0.03 (-11.27%)

0.2947

-0.01 (-4.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-30
Earnings (Next)03-25
Inst Owners12.99%
Inst Owner Change96.71%
Ins Owners0.34%
Ins Owner Change61.52%
Market Cap54.31M
Revenue(TTM)5.26M
Net Income(TTM)-20.57M
Analysts81.82
Price Target6.02 (1942.76%)
Short Float %13.39%
Short Ratio2.27
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)12.85%
Min EPS beat(2)-96.08%
Max EPS beat(2)121.79%
EPS beat(4)2
Avg EPS beat(4)-166.61%
Min EPS beat(4)-695.44%
Max EPS beat(4)121.79%
EPS beat(8)5
Avg EPS beat(8)-72.35%
EPS beat(12)7
Avg EPS beat(12)-48.7%
EPS beat(16)10
Avg EPS beat(16)-30.19%
Revenue beat(2)0
Avg Revenue beat(2)-8.5%
Min Revenue beat(2)-8.69%
Max Revenue beat(2)-8.31%
Revenue beat(4)1
Avg Revenue beat(4)-2.38%
Min Revenue beat(4)-30.01%
Max Revenue beat(4)37.49%
Revenue beat(8)2
Avg Revenue beat(8)-2.75%
Revenue beat(12)3
Avg Revenue beat(12)-1.57%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-17.19%
PT rev (3m)-23.87%
EPS NQ rev (1m)2.49%
EPS NQ rev (3m)-62.5%
EPS NY rev (1m)-1.39%
EPS NY rev (3m)-35.18%
Revenue NQ rev (1m)-15.96%
Revenue NQ rev (3m)-32.21%
Revenue NY rev (1m)-8.35%
Revenue NY rev (3m)-27.28%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.33
P/FCF N/A
P/OCF N/A
P/B 10.75
P/tB 12.61
EV/EBITDA N/A
EPS(TTM)-1.7
EYN/A
EPS(NY)-0.17
Fwd EYN/A
FCF(TTM)-0.09
FCFYN/A
OCF(TTM)-0.09
OCFYN/A
SpS0.03
BVpS0.03
TBVpS0.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -110.19%
ROE -407.06%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-132.52%
ROA(5y)-105.31%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.28
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.8%
Cap/Sales 1.03%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.29
Quick Ratio 1.29
Altman-Z -37.7
F-Score4
WACC8.45%
ROIC/WACCN/A
Cap/Depr(3y)67.77%
Cap/Depr(5y)74.15%
Cap/Sales(3y)82.31%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.19%
EPS Next Y88.56%
EPS Next 2Y38.61%
EPS Next 3Y25.07%
EPS Next 5Y15.88%
Revenue 1Y (TTM)-8.16%
Revenue growth 3YN/A
Revenue growth 5Y-3.61%
Sales Q2Q%-4.05%
Revenue Next Year-1.68%
Revenue Next 2Y19.93%
Revenue Next 3Y62.94%
Revenue Next 5Y89.59%
EBIT growth 1Y8.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year20.17%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-21.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-22.56%
OCF growth 3YN/A
OCF growth 5YN/A

PLUS THERAPEUTICS INC / PSTV FAQ

What is the fundamental rating for PSTV stock?

ChartMill assigns a fundamental rating of 2 / 10 to PSTV.


What is the valuation status of PLUS THERAPEUTICS INC (PSTV) stock?

ChartMill assigns a valuation rating of 1 / 10 to PLUS THERAPEUTICS INC (PSTV). This can be considered as Overvalued.


How profitable is PLUS THERAPEUTICS INC (PSTV) stock?

PLUS THERAPEUTICS INC (PSTV) has a profitability rating of 0 / 10.


Can you provide the financial health for PSTV stock?

The financial health rating of PLUS THERAPEUTICS INC (PSTV) is 4 / 10.


What is the earnings growth outlook for PLUS THERAPEUTICS INC?

The Earnings per Share (EPS) of PLUS THERAPEUTICS INC (PSTV) is expected to grow by 88.56% in the next year.